Replies to post #48555 on Biotech Values

[DewDiligence]

Re: Lotrel patent case

It sounds like the court’s interpretation of the formulation claims in NVS’ patent could go either way. For this reason, I would expect Teva to argue at the trial that the method-of-use claims in NVS’ patent are unenforceable due to obviousness. Regards, Dew

[DewDiligence]

Teva, NVS settle Lotrel US patent case:

http://www.sec.gov/Archives/edgar/data/818686/000081868611000075/lotrelsettlement21072011.htm